.svg){kind=small}
EASL’s International Liver Congress™ in London was a great success. More than 7,000 delegates from 114 countries came together in London and online to discuss the latest science in hepatology.
Our colleagues presented of a 2021 study demonstrating that CRISPR–Cas9 gene editing can be deployed directly into the body to treat ATTR Amyloidosis – presenting longer-term prospects of a cure for the condition.
-min.jpg)
.jpg)
Latest news
Richmond Appoints Lisa Campbell as Director of Regulatory Strategy
April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read moreVon Willebrand Disease – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol
April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read moreEvents
Swiss Biotech Day 2025
5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event
